Tag: Biotechnology

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...

US biotechnology company Enveric Biosciences has reported encouraging laboratory results for EB-003, an experimental psychiatric medicine designed to promote neuroplasticity ...

The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...

The Australian-founded biotechnology company is progressing three investigational treatments, including a synthetic psilocybin therapy for generalised anxiety disorder, as its ...

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...

Global pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, in what would become ...

For much of the past five years, the psychedelic medicine sector has been driven by a relatively straightforward investment thesis. ...